Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact
Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact
Attralus Presents In Vivo Preclinical Data for AT-02 Demonstrating Significant Amyloid Reduction at 18th International Symposium on Amyloidosis

Attralus Presents In Vivo Preclinical Data for AT-02 Demonstrating Significant Amyloid Reduction at 18th International Symposium on Amyloidosis

Sep 6, 2022 Press Releases

PDF Version AT-02 demonstrates amyloid reduction from the heart, kidney, liver, and spleen AT-02 induces in vivo macrophage-mediated phagocytosis of amyloid fibrils AT-02 binds potently to multiple types of amyloid including ATTR, AL, and ALECT2 SAN FRANCISCO, Calif....

Preclinical characterization of AT-02, a pan-amyloid-binding immunoglobulin-peptide fusion protein capable of enhancing phagocytosis and facilitating reduction of amyloid

Sep 6, 2022 Posters & Publications

AUTHORS: Jonathan Wall, Michael L. Klein, Suganya Selvarajah,Spencer Guthrie, Gregory Bell, Christophe Sirac, RoussineCodo, Steve J. Foster, Angela Williams, Tine Richey, Manasi Balachandran, Joseph Jackson, Alan Stuckey, Emily Martin, Sallie Macy, Craig Wooliver, R....
Next Entries »

Recent Posts

  • Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
  • Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
  • Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
  • Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis
  • Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Recent Comments

No comments to show.
COMPANY
About
Management Team
Board of Directors
Scientific Advisory Board
Investors

SCIENCE
Approach
PAR Therapeutics

PIPELINE

NEWS
Press Releases
Posters & Publications

AMYLOIDOSIS
CAREERS
CONTACT

  • Privacy Policy
  • Terms of Service
  • Follow
  • Follow
Attralus logo

Attralus, Inc.
365 Fifth Ave South, Ste 208
Naples, FL 34102

©2026 Attralus, Inc.  All Rights Reserved.